Sarcoma / 2019 / Article / Tab 3

Clinical Study

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

Table 3

Adverse events resulting in dose reduction (DR) or discontinuation (DC) of therapy.

Adverse eventsNGradeAttributionIntervention
EverolimusBevacizumabEverolimusBevacizumab

Abdomen hemorrhage15+DCDC
Alanine aminotransferase13+DCDC
Proteinuria12+DCDC
Proteinuria11+DCDC
Neurologic decline13DCDC
Back pain12DCDC
Pain14DCDC
Thromboembolism13NoneDC
Fatigue13++DRNone
Mucositis22+DRNone
Mucositis11+DRNone
Ear pain11+DRNone

Off-treatment reason for these patients was disease progression.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.